Skip to content
Clinical Trials – home

Zaniewski Bilski Sp. z o.o.

Research site

Poland Ul. Melchiora Wankowicza 5, 10-684 Olsztyn, Poland

  • 9 trials recruiting
  • Colitis ulcerative · Crohn's disease · Erosive oesophagitis
  • Adults and children

About Specializations

Zaniewski Bilski Sp. z o.o. in Olsztyn, Poland specialises in clinical trials of conditions such as Colitis ulcerative, Crohn's disease, Erosive oesophagitis, Gastrooesophageal reflux disease, and other specialisations. This site conducts important research.

Main research areas of the site

Digestive System Diseases

At Zaniewski Bilski Sp. z o.o. in Olsztyn, clinical research in Digestive System Diseases focuses on erosive esophagitis linked to gastroesophageal reflux disease. These studies are designed to compare and confirm the effectiveness of new treatment approaches for healing and maintaining control of this condition.

  • Evaluating therapies for healing erosive esophagitis caused by GERD
  • Assessing treatment options for maintaining long-term healing
  • Comparing new medicines with established acid-reducing treatments

The site’s work in this area supports better care for patients with reflux-related damage to the esophagus and helps clarify which therapies may offer stronger symptom control and healing.

Immune System Diseases

Clinical trials in Immune System Diseases at this research site are centered on moderately to severely active ulcerative colitis and moderately to severely active Crohn’s disease. The research is aimed at testing new therapies that can help induce and maintain remission in these chronic inflammatory conditions.

  • Studying treatments for ulcerative colitis to reduce inflammation and improve remission rates
  • Investigating therapies for Crohn’s disease with the goal of better disease control
  • Comparing active treatment with placebo in both induction and maintenance settings

These trials reflect a strong focus on inflammatory bowel disease research, with attention to both adult and adolescent patients and the need for durable, effective treatment strategies.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ul. Melchiora Wankowicza 510-684 OlsztynPoland
Recruiting now
9 trials
Conditions studied
4

More sites in OlsztynPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

11 clinical trials

Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Phase 2 Randomized Double‑Blind Placebo‑Controlled Study of MH002 in Adults with Mild‑to‑Moderate Ulcerative Colitis Inadequately Controlled by 5‑ASA

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years

Crohn's disease

Recruiting

A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Crohn's disease

Recruiting

A study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A study of duvakitug for patients with moderately to severely active ulcerative colitis to see if it works and is safe as maintenance therapy

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A study testing duvakitug for patients with moderately to severely active ulcerative colitis

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Crohn's disease

Recruiting

Study of icotrokinra for adults with moderately to severely active Crohn's disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Icotrokinra
  • Sponsor:Janssen Cilag International

Testing icotrokinra compared to placebo for adults and adolescents with moderately to severely active ulcerative colitis

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Icotrokinra
  • Sponsor:Janssen Cilag International

Study of linaprazan glurate and lansoprazole to maintain healing in patients with erosive esophagitis caused by acid reflux disease

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Lansoprazole
  • Sponsor:Cinclus Pharma Holding AB (publ)

Comparison of linaprazan glurate versus lansoprazole for healing of erosive esophagitis in adults with gastroesophageal reflux disease

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Lansoprazole
  • Sponsor:Cinclus Pharma Holding AB (publ)
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.